🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Small but significant increase in mortality and decrease in advanced heart failure care in patients admitted with cardiogenic shock on the weekend. The importance of multidisciplinary shock teams cannot be overstated. Michael Nassif Shashank Sinha, MD, MSc, FACC, FAHA, FHFSA Jason N. Katz venu menon

New study from Saint Luke's Mid America Heart Institute investigators Michael Nassif and Mikhail Kosiborod showing a rapid improvement in PA pressures with empagliflozin as measured by CardioMEMS Brett Sperry, MD John T. Saxon, MD John Spertus Anthony Magalski Mark Everley tjfendler

This double-blind study randomly assigned adults with obesity without diabetes to 68 weeks of once-weekly subcutaneous semaglutide or placebo, plus lifestyle intervention. Semaglutide therapy was associated with sustained, clinically relevant weight reduction.

Great story! Example #10000 why you need to listen to your patients

News coverage for the Semaglutide paper. The “New era” would be when we don’t have to worry about cost to the patient. Drugs work when patients can afford them and take them.

Brett Sperry, MD Elsayed Abosalem @md_SsAhmad Babar Basir Arvin Narula @ajaykirtane Arie Blitz, MD, MBA William W. O'Neill Chadi Alraies, MD FACC FSCAI @DrNasrien Amir Kaki, MD Dr. Eric Horlick ECMO Princess ED ECMO Project Utility of IABP with VA ECMO depends on what you need it for. Want ventricular recovery post AMI? There are better options. Want to prevent aortic root thrombus or pulmonary edema in end-stage HF while bridging to VAD? Usually does the trick. Here's video with IABP on/off/on

Why they call Burlington #Vermont New England’s West Coast! #LakeChamplain #WearAMask

Thanks Journal of Cardiac Failure for your interest in cardiac transplantation! We wondered whether or not some of the historical data about risk factors for vasculopathy and death after heart transplantation were valid in the current era of immunosuppressive therapy. 1/n

Finally, our review "Smart #wearable devices in #cardiovascular care: where we are and how to move forward" is out in Nature Reviews Cardiology One of the papers I'm super proud of. Thanks to the phenomenal team who worked on it for the last 1.5 years! rdcu.be/cgdir

Vermonters with Heart disease: get your shot 👇🏼Mary Cushman 🫀🧠🩸 UVM Medical Center UVM CVRI

I practice medicine based on three concepts: 1. Science 2. Treat patients as how you want your family to be treated in healthcare 3. “If anyone saved a life it would be as if he saved the life of the whole humanity.” Quran 5:32 #MedTwitter

Fantastic work from clinical researchers at St. Luke’s Hospital of Kansas City Saint Luke's Mid America Heart Institute David Safley John Spertus

Me: We are what we eat. 5 year old: I don’t want to be an orange.

POV: It's fall in #Vermont 😻🍂 (P: lukamester via Instagram)

AMI Shock ≠ Acute de novo HF ≠ Acute on Chronic HF.. Different patients, different management strategies, different outcomes

In Vermont, many complex cardiac patients spend their winters out of state. Telehealth saves lives in HF! Yet another reason to facilitate interstate tele-visits and instate a “nationwide” licensing!

What we can say about IABP is that it does not reduce mortality from shock following AMI. If you haven’t realized that different cardiogenic shock etiologies are different (including response to therapies) then you need to start rounding in the CCU